Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ra Pharmaceuticals Inc.

Developing oral peptide-like drugs using synthetic amino acids

This article was originally published in Start Up

Executive Summary

Ra Pharmaceuticals Inc. is developing and establishing a new class of drugs called Cyclomimetics. The just-out-of-stealth-mode biotech says these drugs will be orally available peptide therapeutics combining the diversity and specificity of antibodies with some of the benefits of small molecules, including oral dosing and longer half-lives. Its first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts